Header Logo

Connection

Celalettin Ustun to Humans

Back to Details
This is a "connection" page, showing publications Celalettin Ustun has written about Humans.
Celalettin Ustun
Connection Strength
0.675
Humans
  1. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 Jan; 59(1):76-84.
    View in: PubMed
    Score: 0.048
  2. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplant Cell Ther. 2024 Jan; 30(1):114.e1-114.e16.
    View in: PubMed
    Score: 0.048
  3. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis. Blood Adv. 2022 10 25; 6(20):5630-5633.
    View in: PubMed
    Score: 0.045
  4. Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 10; 57(10):1632-1634.
    View in: PubMed
    Score: 0.044
  5. Transplantation provides superior survival high risk myeloid malignancies in older patients. Leuk Lymphoma. 2022 10; 63(10):2494-2498.
    View in: PubMed
    Score: 0.043
  6. Human Herpesvirus-6 Infection and Calcineurin Inhibitor Pain Syndrome Interaction after Umbilical Cord Blood Transplant. Transplant Cell Ther. 2021 05; 27(5):439-440.
    View in: PubMed
    Score: 0.040
  7. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 02; 43(1):e19-e25.
    View in: PubMed
    Score: 0.039
  8. Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv. 2020 05 26; 4(10):2317-2324.
    View in: PubMed
    Score: 0.038
  9. Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
    View in: PubMed
    Score: 0.038
  10. Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 08; 61(8):2008-2011.
    View in: PubMed
    Score: 0.038
  11. DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD? Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):264-266.
    View in: PubMed
    Score: 0.037
  12. Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. Blood Adv. 2019 11 26; 3(22):3709-3712.
    View in: PubMed
    Score: 0.037
  13. Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. Bone Marrow Transplant. 2020 04; 55(4):833-835.
    View in: PubMed
    Score: 0.036
  14. Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies. Infect Dis Clin North Am. 2019 06; 33(2):331-359.
    View in: PubMed
    Score: 0.035
  15. Scedosporium infection disseminated "from toe to head" in allogeneic stem cell transplant recipient: a case report. BMC Infect Dis. 2023 May 25; 23(1):353.
    View in: PubMed
    Score: 0.012
  16. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
    View in: PubMed
    Score: 0.011
  17. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022 01 08; 6(3):828-847.
    View in: PubMed
    Score: 0.011
  18. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021 08 01; 106(8):2295-2296.
    View in: PubMed
    Score: 0.010
  19. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020 10; 34(10):2809-2812.
    View in: PubMed
    Score: 0.010
  20. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820.
    View in: PubMed
    Score: 0.010
  21. Calcineurin-inhibitor induced pain syndrome after stem cell transplant. Leuk Lymphoma. 2020 09; 61(9):2230-2233.
    View in: PubMed
    Score: 0.009
  22. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
    View in: PubMed
    Score: 0.009
  23. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
    View in: PubMed
    Score: 0.009
  24. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2017 Jun; 23(6):971-979.
    View in: PubMed
    Score: 0.008
  25. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2017 May; 23(5):767-775.
    View in: PubMed
    Score: 0.008
  26. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.